Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.

The entities involved

• Arcus Biosciences →

  biopharmaceutical company

  Nothing else this week.

• Leerink partners →

  U.S. investment bank

  • Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
  • A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38
• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12
• SEC →

  Slovak company

  • Waste Connections filed disclosures regarding stock transactions with the SEC.Mon 16:19
  • Choice Hotels filed required insider trading disclosures with the SEC.Mon 16:18

Related events

• Analyst rating targets are affecting stock prices, and required reports regarding ownership stakes are being filed with the SEC for Bank of America and KBR, Inc.Sep 9
• Analyst upgraded Ironwood Pharmaceuticals to 'hold' rating, concurrent with insider selling disclosures filed with the SEC.Sat 10:54
• Moderna stock activity, including institutional purchases and analyst ratings, was disclosed to the SEC.Sep 9
• Arcus Biosciences filed required reports with the Securities and Exchange Commission.Sep 4
• Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Jun 10